glp 1 microdosing treatment minneapolis GLP-1 What is GLP-1 Microdosing? |

This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards

Conclusion: This meta-analysis of RCTs provides reassuring evidence that GLP-1 receptor agonists were not associated with an increased risk of gastrointestinal cancers, with signals suggesting a possible reduction in colorectal and liver cancer incidence that should be interpreted cautiously

The formulation warning Oral semaglutide (Rybelsus) should not be used during breastfeeding

Finally, although the risk of bias was generally low across studies, sponsorship bias cannot be ruled out given that a substantial proportion of the included RCTs were industry-funded